Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Opinion CV Team Dispatch

December 2025 Dispatch for the CV Team

L.A. McKeown

December 23, 2025

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Daily News

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

Michael O'Riordan

August 21, 2024

News Daily News

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

Todd Neale

January 12, 2024

News Opinion CV Team Dispatch

April 2023 News Roundup

L.A. McKeown

April 01, 2023

News Conference News ACC 2023

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Shelley Wood

March 08, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Michael O'Riordan

December 07, 2022

News Conference News AHA 2022

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Michael O'Riordan

November 06, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

Michael O'Riordan

February 05, 2020

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Michael O'Riordan

May 08, 2019

News Daily News

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

Michael O'Riordan

November 26, 2018

News Daily News

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

Michael O'Riordan

November 23, 2018

News Conference News EAS 2018

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Yael L. Maxwell

May 11, 2018

News Daily News

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Michael O'Riordan

September 16, 2016

Advertisement

January 2026 Dispatch for the CV Team

December 2025 Dispatch for the CV Team

November 2024 Dispatch for the CV Team

‘Disproportionate’ Suicide/Self-Harm Signal With Semaglutide: WHO Database

FDA: No Signs of Link Between GLP-1s and Suicidal Thoughts, Actions

April 2023 News Roundup

Keto Diet Linked to Hypercholesterolemia, Higher ASCVD Risk

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Common ‘Heart’ Supplements Can’t Beat Statins: SPORT

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

Meat Consumption Linked to Small Rises in CVD, All-Cause Mortality Risks

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

FDA Tallies Cases of Fournier Gangrene in Patients Taking SGLT2 Inhibitors

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

EAS Consensus Document Examines Safety of Statins Beyond Muscle Symptoms

Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content